Thermo Fisher Scientific (TMO) stock experienced a significant Power Inflow on October 23rd, indicating potential institutional buying and a possible uptrend. Traders utilizing order flow analytics see this as a bullish signal, suggesting an entry point for capitalizing on the expected upward momentum. Learn more about how Power Inflow impacts TMO’s stock and how to leverage order flow analytics for informed trading decisions.
Thermo Fisher Scientific Inc. (NYSE: TMO) reported third-quarter revenue of $10.59 billion, narrowly missing analyst expectations. While revenue growth improved sequentially, it remained flat compared to the prior year. Despite the revenue miss, adjusted earnings per share beat estimates. The company reaffirmed its 2024 sales guidance and adjusted its EPS guidance slightly upward. TMO shares traded lower following the earnings report.
Thermo Fisher Scientific’s Greenville facility, a major contract drug manufacturing site, has been flagged for repeated regulatory violations despite its potential for growth in the injectables sector. While the FDA has not taken regulatory action, concerns remain about the plant’s quality control practices, particularly after recent issues with the production of Wegovy and Beyfortus.
Thermo Fisher Scientific (TMO) continues to impress with its strategic partnerships and product launches, but macroeconomic challenges and declining COVID-19 testing demand pose hurdles to its growth. The company’s strong track record of earnings beats and its expansion into new markets suggest long-term potential, but investors should remain aware of the current economic climate.
Thermo Fisher Scientific Inc. reported mixed financial results for the first quarter of 2024, with revenue beating estimates but organic growth declining. Revenue came in at $10.34 billion, a 3% decrease year-over-year but above the consensus of $10.17 billion. Adjusted earnings per share (EPS) of $5.11 surpassed expectations of $4.71 and increased from $5.03 in the prior year quarter. Despite revenue declines in certain segments, the company’s strong commercial execution and operational discipline drove overall performance. Thermo Fisher raised its full-year 2024 guidance, projecting revenue between $42.3 billion and $43.3 billion and adjusted EPS between $21.14 and $22.02.
